INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 177 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2020. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $315,000 | +67.6% | 12,256 | 0.0% | 0.00% | +50.0% |
| Q1 2020 | $188,000 | -97.5% | 12,256 | -94.4% | 0.00% | -97.3% |
| Q4 2019 | $7,494,000 | +406.7% | 218,415 | +10.4% | 0.07% | +311.1% |
| Q3 2019 | $1,479,000 | -2.4% | 197,927 | +69.6% | 0.02% | -14.3% |
| Q2 2019 | $1,515,000 | +13.5% | 116,684 | +6.5% | 0.02% | +10.5% |
| Q1 2019 | $1,335,000 | +62.8% | 109,584 | +52.2% | 0.02% | +35.7% |
| Q4 2018 | $820,000 | +255.0% | 72,014 | +577.8% | 0.01% | +366.7% |
| Q3 2018 | $231,000 | +1.3% | 10,625 | -17.8% | 0.00% | -25.0% |
| Q2 2018 | $228,000 | -6.2% | 12,920 | -23.0% | 0.00% | 0.0% |
| Q4 2017 | $243,000 | +32.1% | 16,770 | +43.7% | 0.00% | 0.0% |
| Q3 2017 | $184,000 | -87.6% | 11,670 | -78.1% | 0.00% | -87.1% |
| Q1 2016 | $1,480,000 | – | 53,224 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |